Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
The Cell Cycle Control System01:28

The Cell Cycle Control System

3.5K
The cell cycle regulation directs how a cell proceeds from one phase to the next and begins mitosis. The cell cycle control system includes intracellular regulatory molecules and external triggers. They provide "stop" or "advance" signals and operate at specific cell cycle stages termed checkpoints to ensure that a particular process is completed before the cell advances to the next phase.
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...
3.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Negative Regulator Molecules01:23

Negative Regulator Molecules

35.9K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.9K
Positive Regulator Molecules02:39

Positive Regulator Molecules

5.7K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.7K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Multiomic profiling of responses to clinical and novel bisphosphonates reveals extraskeletal effects on ageing related signatures.

Signal transduction and targeted therapy·2026
Same author

Molecular Solution to the Paradox of Ancient Brain Preservation.

Journal of proteome research·2026
Same author

Towards light-coupled sample preparation for time-resolved cryoEM studies.

IUCrJ·2026
Same author

Discovery of Tcf7 regulators with clonally-resolved CRISPR screens identifies Trim28 as a mediator of CD8 T cell differentiation in tumors.

bioRxiv : the preprint server for biology·2026
Same author

USP24 is a cross-reactive DUB targeting MOV10 to regulate IFN-I production.

Nature communications·2026
Same author

Multidimensional proteomics and explainable AI feature selection identify cross-platform lung cancer molecular signature in blood plasma.

Communications medicine·2026

関連する実験動画

Updated: Sep 10, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

サイクリンA/BRxL阻害剤によるG1-Sチェックポイント障害がんの標的化

Shilpa Singh1, Catherine E Gleason2, Min Fang3

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Nature
|August 20, 2025
PubMed
まとめ

新しいマクロサイクルペプチドは,サイクリン相互作用を抑制することによって,小細胞肺がん (SCLC) 細胞を選択的に殺します. これらの経口薬は,スパインドルアセンブリチェックポイントの活性化によってアポトーシスを誘発することで,E2F駆動がんを標的とする.

さらに関連する動画

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

27.6K

関連する実験動画

Last Updated: Sep 10, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

27.6K

科学分野:

  • 腫瘍学
  • 分子生物学
  • ガン治療薬

背景:

  • 小細胞肺がん (SCLC) は,RB1とTP53の変異によって特徴づけられ,E2Fの活動が失調する.
  • E2Fの過剰活性化は,細胞サイクル進行に不可欠であるが,アポトーシスを促進し,治療上の脆弱性を提示する.
  • 特にRxLモチーフをターゲットにすることが困難でした.

研究 の 目的:

  • サイクリンRxLモチーフを標的とした,細胞に浸透し,経口で生物利用可能な新しいマクロサイクリックペプチドを開発する.
  • SCLCを含むE2F活性が高いがん細胞におけるこれらの阻害剤の有効性を調査する.
  • これらの新しい阻害剤の抗がん効果の基礎となる分子機構を明らかにする.

主な方法:

  • サイクリンAとサイクリンBのRxLモチーフ (サイクリンA/Bi) を標的とする二重抑制剤の開発
  • 高E2F活性を持つSCLCやその他の癌細胞の選択的殺戮の評価
  • アポトーシス誘導のメカニズムを特定するために遺伝子スクリーンを利用する.
  • サイクリンB,CDK2,およびスピンドルアセンブリチェックポイントの活性化の役割を調査する.
  • 化学療法に耐性のあるSCLC患者からの異種移植における抗腫瘍活性評価

主要な成果:

  • サイクリンA/ Biは選択的にSCLCやその他のE2F活性を持つ癌細胞を殺す.
  • アポトーシスは,サイクリンBとCDK2依存のスパインドルアセンブリチェックポイントの活性化によって誘発される.
  • サイクリンA/ BiはサイクリンA- E2FとサイクリンB- MYT1RxLの相互作用を阻害し,E2FとサイクリンBの過剰活性化につながる.
  • ネオモルフなサイクリンB-CDK2複合体が形成され,ミトスの細胞死を引き起こします.
  • 口服されたサイクリンA/ Biは,SCLCの異種移植において有意な抗腫瘍作用を示した.

結論:

  • サイクリンRxLの相互作用を阻害する経口生物利用可能なマクロサイクリックペプチド (サイクリンA/ Bi) が開発された.
  • サイクリンA/ Biは,アポトーシスを誘発することで,SCLCを含むE2F誘発がんを効果的に標的とする.
  • これらの発見は,化学療法に耐性のあるSCLCおよび他のがんの治療におけるサイクリンA/ Biの治療可能性を裏付けています.